ProLynx has a number of ongoing programs- very early stage to clinical stage.  These are aimed at improving the pharmacokinetics of known drugs or close-relatives to provide long acting therapeutics with improved pharmacokinetic properties.

  • PLX038 is a novel long-acting releasable PEGylated prodrug of the anticancer agent SN-38.  Currently, the drug is just completing dose escalation at MD Anderson, and a combination trial of PLX038 with a PARP inhibitor will be initiated in early 2020.
  • We have an early-stage program aimed at developing a long-acting PEG-PARP inhibitor for oncology.  A single injection in mice causes dramatic tumor inhibition.  Our PEG-PARP inhibitor can be used with DNA damaging agents without severe toxicity.
  • We have an early program in using our technology to reduce CMax and increase the exposure of a) an IL-2 mutein specific for the high affinity IL-2 receptor, and b) IL-15.
  • Currently, replacement therapy for PTH in hypoparathyroidism requires subcutaneous injections of PTH each day.  We have developed a once-weekly PTH which shows a low peak-to-trough ration. It should qualify for 505b2 and orphan drug designations. Pharmacodynamic studies are being performed, and we anticipate the drug will enter preclinical toxicology studies in 2020.
  • PLX039 is our QMo GLP-1 RA that shows excellent PK and PD in models of T2D.  We believe this is the longest acting GLP-1 RA available.  We are seeking to license this molecule for T2D in humans, and in the meantime are developing the product for veterinary use.
  • We are collaborating with a major Pharmaceutical company on a long-acting small molecule for intravitreal therapy fo an eye disease.

Following are brief descriptions of long-lasting drug candidates that are available for licensing click here.